Clinical Review on Fenofibrate-Statin Therapy for Remnant Cholesterol

A document authored by Vikrama Raja and last updated on 2026-06-04 discusses the role of remnant cholesterol in cardiovascular risk. The 162.3 KB text file reviews evidence from clinical trials and real-world studies spanning up to two decades on fenofibrate-statin combination therapy. It focuses on managing dyslipidemia and reducing residual cardiovascular risk associated with triglyceride-rich lipoproteins.

Use Cases

• Reviewing the evidence for fenofibrate-statin combination therapy based on the clinical trial and real-world study data mentioned.
• Analyzing the role of remnant cholesterol and non-HDL-C in cardiovascular risk assessment based on the described concepts.
• Studying the safety and tolerability of long-term fenofibrate use based on the two-decade studies referenced.

Strengths

• The document cites evidence from clinical trials and real-world studies spanning up to two decades.
• It is published under a CC-BY-4.0 license, allowing for open sharing and reuse.
• The author is identified as Vikrama Raja, providing attribution.

Limitations

• The dataset is a 162.3 KB DOCX file, indicating a limited scope of textual content rather than structured data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Authored document, likely a review or summary.

Freshness

Last updated 2026-06-04 04:27:23; freshness should be verified.